FIREBRICK PHARMA LIMITED — Capital/Financing Update 2023

==> picture [170 x 50] intentionally omitted <==

31 October 2023

ASX Announcement

Firebrick Receives $1.81m R&D Tax Incentive

• $1.81 million R&D tax incentive for R&D expenditure in FY23

Firebrick Pharma Limited (ASX:FRE) ( Company or Firebrick ) is pleased to announce that it has received an RDTI (R&D Tax Incentive) payment of $1,816,127 for eligible R&D expenditure incurred in 2022/23.

The incentive payment related to $3.95 million in reported R&D costs in the FY23 year, primarily associated with the Company’s two clinical trials: (1) Phase 3 trial of Nasodine[®] Nasal Spray (“Nasodine”) as a treatment for the common cold, and (2) Phase 2 trial of Nasodine in COVID-19.

“We welcome the valuable injection of non-dilutive funds from the R&D tax incentive” said Dr Stephen Goodall, Executive Director and Chief Operating Officer of Firebrick Pharma.

This announcement was authorised for release by Dr Stephen Goodall, Executive Director and Chief Operating Officer of Firebrick Pharma.

• ENDS -

About Firebrick (ASX:FRE)

Firebrick is a pharmaceutical company founded in 2012 with the mission to develop and commercialise a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The Company owns numerous patents, know-how and other intellectual property around the use of intranasal povidoneiodine.

Media enquiries: Investor enquiries: Heidi Cuthbert [email protected] +61 411 272 366 [email protected]

Firebrick Pharma Ltd | ABN 64 157 765 896 | L10, 440 Collins St. Melbourne, VIC, 3000, Australia P: 1300 301 874 | W: firebrickpharma.com